Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Quick answer: In head-to-head trials, tirzepatide (a dual GLP-1/GIP receptor agonist) produced greater weight loss than semaglutide (a single GLP-1 agonist) 20.2% vs 13.7% over 72 weeks in SURMOUNT-5 though semaglutides single-pathway selectivity keeps it valuable in research
These neurotransmitters are responsible for regulating mood and emotional state
This helps them eat smaller portions and reduce calorie intake, which can lead to weight loss over time
The usual treatment involves stopping the injection and giving supportive care
Although numerous peptides participate in this axis, glucagon-like peptide-1 (GLP-1) plays a central role
